Innovative companies in the pharma/biotech field face generic competition earlier than ever before. It is vital for companies to have a cohesive IP strategy as a drug progresses through clinical trial milestones to develop strategic claiming strategies and maximize patent term. Once a drug reaches Phase II or Phase III clinical trials, it is often advantageous for companies to conduct a “health check” on their IP portfolios, critically analyzing issued patents and pending applications for potential weaknesses and addressing them well before a New Drug Application (NDA) submission and product launch.
In this webinar, the panel will discuss several examples of issues that can arise during an IP portfolio “health check,” including:
- Claim construction pitfalls
- Written description/enablement compliance
- Obviousness-type double patenting
- Inventorship
- Orange Book listing and patent term maximization strategies
Recorded: View On-Demand
Speakers:
Michele Bosch
Pier DeRoo
Moderator:
Charles Collins-Chase
Date:
Wednesday, September 24, 2019
Time:
10:00 - 11:00 a.m. PDT
1:00 - 2:00 p.m. EDT
19:00 - 20:00 p.m. CEST
Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.
Tags
claim construction, new drug application (NDA), Obviousness-type Double Patenting (OTDP), Orange Book, 2019 Top Insights
